Objective: To evaluate response rates and survival in adults developing post-transplant lymphoproliferative disorder (PTLD) following liver transplantation.
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PTLD shares common features with other immunodeficiency related lymphomas such as a preferential representation of non-Hodgkin lymphoma (NHL) versus Hodgkin lymphoma, B-cell origin, involvement of extranodal and unusual sites, high-grade histology, aggressive clinical behaviour and frequent association with EBV infection. [12] [13] [14] The current histological classification of PTLD is described in the World Health Organisation (WHO) classification of haematopoietic tumours and classifies PTLD into early lesions, polymorphic and monomorphic PTLD. The latter is then divided into B-and T-cell lymphomas that resemble those occurring in the immunocompetent state. 15 Treatment can be challenging with a higher reported rate of treatmentrelated death compared with lymphomas in the immunocompetent setting. RIS is the main stay of treatment for early and polymorphic PTLD, but this is insufficient for treatment of most monomorphic subtypes which usually require treatment with combination chemotherapy. 16 More recently, the monoclonal anti-CD20 antibody rituximab has been used as first-line treatment of B-cell PTLDs, reserving chemotherapy for those with more high-risk features or those with an incomplete response. 17, 18 More novel cellular therapies, including EBV-specific cytotoxic T-cells (CTLs), have also been investigated and are in clinical development. 19 This study from the largest liver transplant unit in the United
Kingdom reports the outcome of a retrospective series of adult patients developing PTLD.
| PATIENTS AND METHODS

| Patients
This retrospective study included 45 adult patients who received a liver transplant at King's College Hospital, London, UK, between 1986
and 2014 and subsequently developed PTLD. Patients were identified through local liver and haematology electronic databases and pharmacy records. Data were collected from electronic patient records and clinical notes. Data cut-off was 31st January 2017.
| Diagnosis and staging
The histological diagnosis of lymphoma was confirmed by biopsy according to the classification in use at the time. 
| Treatment
The management and treatment of all patients was reviewed and agreed upon by the King's College Hospital lymphoma multidisciplinary 
| Definitions
The primary end point was overall response rate (ORR). Secondary end points were progression-free survival (PFS) and OS. OS was measured from the date of diagnosis of PTLD to the date of last follow-up or death. PFS was determined in patients achieving a CR and was measured from the date of CR to the date of disease relapse. Early PTLD was defined as occurring in the first 24 months post-transplant and late after 24 months.
| Response evaluation
Response to treatment was determined 4-6 weeks following the last cycle of chemotherapy according to standard criteria at the time by the treating physician. 21 Response was assessed by CT scan in 30 (67%) patients and
18
F-FDG-PET/CT in 11 (24%). In addition, based on the site of disease, one patient had a colonoscopy and one a gastric endoscopy as part of disease reassessment. Four patients died prior to response assessment.
| Statistical analysis
Statistical analysis was performed using GraphPad PRISM® version 5 (GraphPAD Software, San Diego, CA, USA). The Kaplan-Meier method was used to construct OS and PFS curves. A P-value less than .05 was considered statistically significant. patients (67%) with stage 1 disease had extranodal involvement, including 4 with small bowel involvement, 2 with large bowel and 1 with involvement of the liver graft. Overall, the most commonly involved extranodal sites were the liver graft in 10 (22%), followed by the bone marrow in 7 (16%) and small bowel in 6 (13%). The immunosuppression regimen at the time of PTLD diagnosis is shown in Table 1 .
| RESULTS
| Patient characteristics
| Treatment
The initial PTLD therapy is shown in Figure 1 
| Response to treatment
The overall response rate to treatment was 76% with 26 (58%) patients achieving a CR and 8 patients achieving a partial response (PR).
Eleven patients (24%) had progressive disease. In univariate analysis, 
| Progression-free survival and overall survival
At a median follow-up of 27 months (range 1-273), the median OS is 50 months (Figure 2A 
| DISCUSSION
This retrospective series from the UK's largest liver transplant unit demonstrates an incidence of PTLD following liver transplant of approximately 1%, which is at the lower end of that reported in prior studies. 2, 4, 6 The most common indication for transplantation in this series is autoimmune liver disease, which is in keeping with the known higher incidence of PTLD in patients transplanted for autoimmune diseases. Transplantation for autoimmune disease represents only 10%-15% of all indications for liver transplantation in our unit. The higher incidence of PTLD is likely due to the more intensive immune-suppression used post-transplant and may also reflect immune-suppression prior to transplantation either for the liver disease itself or for associated inflammatory bowel disease and other autoimmune conditions. 6, 22, 23 Although previously it has been reported that the majority of PTLD cases occur early posttransplant, within the first 1-2 years, more recent data suggest that late-onset PTLD is more common. 6, 24 This is in keeping with our data in which 71% of cases occurred beyond 24 months. However, in contrast to other series in which PTLD occurring early is usually In a series of 80 patients with PTLD following all solid organ transplantation, the 3-year OS was 62%. 24 Most studies have reported a high rate of treatment-related death in the order of 5%-30%; however, there was only one treatment death in our series. [16] [17] [18] The outcome for those patients achieving a CR appears favourable with a 5-year PFS of 83%. Of the 5 patients that relapsed 3 obtained a second CR.
As expected, the most common histological subtype of PTLD was monomorphic B-cell lymphoma. In general, the prognosis of this subtype has improved with the introduction better supportive care (use of granulocyte stimulating factor and prophylactic antibiotics), the use of rituximab and the recognition that not all patients require cytotoxic chemotherapy. In the phase 2 PTLD-1 study, 70
patients with CD20-positive lymphoma were treated sequentially with 4 doses of weekly rituximab followed by 4 cycles of CHOP chemotherapy. The ORR to single-agent rituximab was 60% with 20% CR and following CHOP chemotherapy 90% (68% CR). PFS at 3 and 5 years was 69% and 66% with a median OS of 6.6 years.
Treatment-related death was 11%. 17 A follow-on phase 2 study Treatment-related death occurred in 8% of patients. The median OS was 6.6 years with a 3-year OS of 70%. 18 In our study, the use of rituximab did not in itself increase response rates or OS in patients with B-cell lymphoma, although these data need to be interpreted with caution as the patients treated with and without rituximab were diagnosed and treated in different decades with differing treatment approaches. For patients treated in more recent years, 7 of 10 patients who received single-agent rituximab achieved a CR and were able to avoid the use of cytotoxic chemotherapy. This may have contributed to the overall low treatment-related death and also confirms that immune-suppression-related lymphomas may not require conventional anthracycline-based chemotherapy regimens as there is the opportunity to modulate the immune system to achieve meaningful responses. Avoidance of chemotherapy is also desirable to decrease long-term sequelae such as cardiac failure and peripheral neuropathy.
In this study, we did not identify any impact of several clinical variables on response rates or OS including age, stage, early or late PTLD, EBV status and graft involvement. 6, 24, 26 This is possibly due to sample size. We included one patient in this study who was treated with single-agent rituximab for EBV reactivation alone with no clinical evidence of PTLD. The role of EBV monitoring and pre-emptive treatment in adults undergoing solid organ transplantation is controversial,
given the lack of consensus of a threshold EBV copy number that is sufficiently sensitive and specific to justify treatment. 27 In general, our centre does not pre-emptively treat EBV reactivation.
This study provides real-world experience of the treatment of PTLD following liver transplantation. It confirms that favourable outcomes can be achieved and that intensive chemotherapy regimens may not be required to achieve meaningful responses even in histologically aggressive tumours. 
